Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07389473

Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

The study aims to verify if the Gaize ocular device can effectively identify eye movements indicative of prescribed psychotropic medication usage by employing Drug Recognition Expert (DRE) testing protocols within a controlled virtual environment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Gaize

Philadelphia, Pennsylvania, 19130, United States

Location status: Recruiting

Location contact

Apurva Raje Research Coordinator / Principal Investigator

CONTACT

[email protected]

732-397-1795

About this study

The use of psychotropic (psychiatric) medications for various psychiatric disorders is a common practice. Long-term use of such medications necessitates monitoring due to potential side effects, including ophthalmic issues (1). The Gaize VR headset represents a novel approach to monitoring these effects by utilizing Drug Recognition Expert (DRE) testing methods to detect eye movements associated with substance use.

Psychotropic medications have been associated with a range of visual and oculomotor side effects, which can impact patient safety and quality of life (2). The prevalence of these effects in long-term users is not fully characterized in the literature, and traditional methods of assessment may miss subclinical alterations in eye movement or function. Eye movement patterns are altered predictably by the use of various substances, such as cannabis, alcohol, and other psychoactive drugs. DRE protocols utilize oculomotor tests to infer recent drug use (3). These protocols are, however, often subjective and require trained personnel to administer, leading to potential variability in assessment and risk of false positives. Advances in virtual reality technology have allowed for more precise and controlled assessment of eye movements. VR headsets can isolate and measure specific eye movement parameters, potentially providing a more accurate and objective measure of oculomotor function and impairment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged between 18 and 65, having given written informed consent to participate in the research trial.
  • Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.
  • Normal or corrected to normal vision using either glasses or contact lenses, or surgery.

Exclusion criteria

  • Enrolled in, or participated in another clinical trial within 30 days before the study
  • Having a prosthetic eye, missing eye, or wearer of an eye patch LASIK or other eye surgery within the prior 21 days.
  • Had your eyes dilated by a medical doctor in the previous 24 hours.
  • Photosensitive epilepsy
  • Diagnosed with clinical blindness
  • Medical Conditions: Participants with medical conditions or medications that could significantly affect cognitive and motor functions are excluded. Participants with conditions such as Glaucoma, macular degeneration, cataracts, lazy eye (amblyopia), or optic neuritis, or genetic anisocoria (unequal pupil size) will be excluded.
  • Current or past head inject/ traumatic brain injury (TBI)
  • Pregnancy: Pregnant individuals will be excluded from the study due to the potential risks associated with psychiatric medications.
  • History of Severe Motion Sickness: Participants with a history of severe motion sickness in VR environments may be excluded, as they may not tolerate the VR headset well.
  • Potential participants who are unable to provide consent for the study.

Treatment and study plan

Prescription Psychotropic Medications

Drug

Currently using a psychiatric medication as prescribed by a healthcare professional for longer than 3 months.

Primary outcomes

  1. Collection of Ophthalmic Data

    Time frame: 1 Day

    Accuracy of the Gaize device in detecting eye-movement metrics consistent with prescribed psychotropic medication use, as determined by Drug Recognition Expert (DRE) testing protocols in a controlled virtual environment.

Study contacts

Contact information is provided by the study sponsor or research team.

Apurva Raje Research Coordinator / Principal Investigator, BA

CONTACT

[email protected]

732-397-1795

Rob Kaufmann CTO

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Gaize

Industry

Registry information

Official study title

An Observational Study to Evaluate the Effects of Long-term Use of Psychotropic Medications on Eye Movement Patterns With the Gaize Device

Acronym: Rx Meds Gaize

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Feb 5, 2026
Registry last updated
Feb 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.